An official website of the United States government
NIH Websites Are Changing Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Trial Status: active
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as
GSK6042981), is effective in treating adults with a type of cancer called
Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The
study will see if IDRX-42 works well and is safe for participants whose GIST has spread
or cannot be surgically removed, and who have already taken the drug imatinib.
Participants whose disease worsens after receiving sunitinib in this study may cross over
to receive GSK6042981, at investigator's discretion and if additional eligibility
criteria are met.
Inclusion Criteria
Participants with histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.
Documented disease progression on or intolerance to imatinib administered for first-line treatment of unresectable/metastatic disease.
Documented mutation status of KIT and/or PDGFRA using a tissue based next-generation sequencing or polymerase chain reaction (PCR) assay.
Tumor tissue must be available for retrospective biomarker analysis. Sample may be archival or new biopsy.
Exclusion Criteria
GIST that is both KIT and PDGFRA wild-type or known to harbor an activating PDGFRA exon 18 mutation.
Known untreated or active central nervous system metastases.
Participants with a known allergy or hypersensitivity to any component of IDRX-42 (GSK6042981) or sunitinib. Participants with a history of Stevens-Johnson syndrome on a prior Tyrosine kinase inhibitor (TKI) are excluded.
Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07218926.
